Combination therapy of iPS-NKT cell and DC/Gal (Combination therapy of iPS-NKT cell and DC/Gal)

General Information
Clinical trials phase	Phase 1
Start date (estimated)	2023-05-01
Clinical feature	Label head and neck cancer Link http://purl.obolibrary.org/obo/DOID_11934 Description An organ system cancer that arises in the head or neck region. This region includes the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Administrative Information
ICTRP weblink	https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-jRCTa030220741
Other study identifiers	Name jRCTa030220741 Description Japan Registry of Clinical Trials (jRCT)
Source weblink	https://jrct.niph.go.jp/en-latest-detail/jRCTa030220741
Sponsors	Tomohisa Iinuma
Cells
Which differentiated cell type is used	Label natural killer cell Link http://purl.obolibrary.org/obo/CL_0000623 Description A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells.
Recruitment
Recruitment Status	Unknown Status
Comment recruitment status	Pending
Estimated number of participants	6